AN2 Therapeutics, Inc. (ANTX)
NASDAQ: ANTX · Real-Time Price · USD
4.740
-0.060 (-1.25%)
At close: Apr 28, 2026, 4:00 PM EDT
4.500
-0.240 (-5.06%)
After-hours: Apr 28, 2026, 5:48 PM EDT
AN2 Therapeutics Income Statement
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
| FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
| Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
| Selling, General & Admin | 13.34 | 14.07 | 14.76 | 12.75 | 4.67 | |
| Research & Development | 24.77 | 40.49 | 54.87 | 29.51 | 16.91 | |
| Operating Expenses | 38.11 | 54.55 | 69.64 | 42.26 | 21.57 | |
| Operating Income | -38.11 | -54.55 | -69.64 | -42.26 | -21.57 | |
| Interest & Investment Income | 2.93 | 5.47 | 4.86 | - | 0.07 | |
| Currency Exchange Gain (Loss) | - | - | - | - | -0.04 | |
| Other Non Operating Income (Expenses) | 0 | 0 | 0.04 | 1.31 | - | |
| EBT Excluding Unusual Items | -35.17 | -49.09 | -64.73 | -40.96 | -21.54 | |
| Merger & Restructuring Charges | - | -2.23 | - | - | - | |
| Pretax Income | -35.17 | -51.32 | -64.73 | -40.96 | -21.54 | |
| Net Income | -35.17 | -51.32 | -64.73 | -40.96 | -21.54 | |
| Preferred Dividends & Other Adjustments | - | - | - | 1.82 | 6.52 | |
| Net Income to Common | -35.17 | -51.32 | -64.73 | -42.78 | -28.06 | |
| Shares Outstanding (Basic) | 30 | 30 | 24 | 15 | 3 | |
| Shares Outstanding (Diluted) | 30 | 30 | 24 | 15 | 3 | |
| Shares Change (YoY) | 1.30% | 26.39% | 53.85% | 481.46% | 2.71% | |
| EPS (Basic) | -1.16 | -1.72 | -2.74 | -2.79 | -10.64 | |
| EPS (Diluted) | -1.16 | -1.72 | -2.74 | -2.79 | -10.64 | |
| EBIT | -38.11 | -54.55 | -69.64 | -42.26 | -21.57 | |
Source: S&P Capital IQ. Standard template.
Financial Sources.